FAS and acute lymphoblastic leukemia: Moreover, NALM-6/HDR has some distinct characters, including depression in AMPK, mTORC1, glycolysis and FAS pathway, which may hint that the previous therapeutic strategies, such as targeting AMPK, mTORC1, glycolysis and FAS pathway, could not reverse the GC resistant, or even induce some subtype of ALL aggravation.